PRMT5 Promotes Pancreatic Cancer Tumorigenesis via Positive PRMT5/C-Myc Feedback Loop

Abstract

The oncogenic role and underlying mechanism of PRMT5 in pancreatic ductal adenocarcinoma (PAAD) remained to be elucidated. In this study, we aimed to investigate the oncogenic role, underlying molecular mechanisms, and potential therapeutic value of PRMT5 in PAAD. PRMT5 was significantly upregulated in pancreatic cancer than adjacent nontumor pancreas, which was positively correlated with poor prognosis. Genetic and pharmacological inhibition of PRMT5 suppressed PAAD proliferation in vitro and in vivo, exhibiting promising therapeutic effect in vivo. Mechanistically, PRMT5 directly bound to the promoter region of c-Myc and activated its transcription. Transcriptionally activated c-Myc in turn inhibited proteasome-mediated degradation of PRMT5 and enhanced its protein stability, resulting in increased PRMT5 expression. The maintained PRMT5 further enhanced the transcription of c-Myc. In conclusion, PRMT5 forms a positive feedback loop with c-Myc to promote the proliferation of pancreatic cancer. Targeting this oncogenic communication may represent a novel and potential therapeutic approach for pancreatic cancer.

Keywords

pancreatic cancer / PRMT5 / c-Myc / positive feedback loop / proliferation / therapeutic targets

References

[1] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer Statistics, 2021,” CA: A Cancer Journal for Clinicians 71, no. 1 (2021): 7-33.

[2] Q. Wu, M. Schapira, C. H. Arrowsmith, and D. Barsyte-Lovejoy, “Protein Arginine Methylation: From Enigmatic Functions to Therapeutic Targeting,” Nature Reviews Drug Discovery 20, no. 7 (2021): 509-530.

[3] X. Chen, R. X. Chen, W. S. Wei, et al., “PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder Through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition,” Clinical Cancer Research 24, no. 24 (2018): 6319-6330.

[4] S. S. Tarighat, R. Santhanam, D. Frankhouser, et al., “The Dual Epigenetic Role of PRMT5 in Acute Myeloid Leukemia: Gene Activation and Repression via Histone Arginine Methylation,” Leukemia 30, no. 4 (2016): 789-799.

[5] S. K. Tewary, Y. G. Zheng, and M. C. Ho, “Protein Arginine Methyltransferases: Insights Into the Enzyme Structure and Mechanism at the Atomic Level,” Cellular and Molecular Life Sciences 76, no. 15 (2019): 2917-2932.

[6] G. V. Kryukov, F. H. Wilson, J. R. Ruth, et al., “MTAP Deletion Confers Enhanced Dependency on the PRMT5 Arginine Methyltransferase in Cancer Cells,” Science 351, no. 6278 (2016): 1214-1218.

[7] Y. Wu, Z. Wang, L. Han, et al., “PRMT5 regulates RNA m6A Demethylation for Doxorubicin Sensitivity in Breast Cancer,” Molecular Therapy 30, no. 7 (2022): 2603-2617.

[8] P. Kalev, M. L. Hyer, S. Gross, et al., “MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage,” Cancer Cell 39, no. 2 (2021): 209-224.

[9] J. Zhang, X. Fan, Y. Zhou, L. Chen, and H. Rao, “The PRMT5-LSD1 Axis Confers Slug Dual Transcriptional Activities and Promotes Breast Cancer Progression,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 191.

[10] M. Rengasamy, F. Zhang, A. Vashisht, et al., “The PRMT5/WDR77 Complex Regulates Alternative Splicing Through ZNF326 in Breast Cancer,” Nucleic Acids Research. 45, no. 19 (2017): 11106-11120.

[11] F. Orben, K. Lankes, C. Schneeweis, et al., “Epigenetic Drug Screening Defines a PRMT5 Inhibitor-sensitive Pancreatic Cancer Subtype,” JCI Insight 7, no. 10 (2022): e151353.

[12] Y. Sun, X. Jin, J. Meng, et al., “MST2 methylation by PRMT5 Inhibits Hippo Signaling and Promotes Pancreatic Cancer Progression,” Embo Journal 42, no. 23 (2023): e114558.

[13] L. Ge, H. Wang, X. Xu, et al., “PRMT5 promotes Epithelial-mesenchymal Transition via EGFR-β-catenin Axis in Pancreatic Cancer Cells,” Journal of Cellular and Molecular Medicine 24, no. 2 (2020): 1969-1979.

[14] X. Wei, J. Yang, S. J. Adair, et al., “Targeted CRISPR Screening Identifies PRMT5 as Synthetic Lethality Combinatorial Target With Gemcitabine in Pancreatic Cancer Cells,” Proccedings of the National Academy of Sciences of the United States of America 117, no. 45 (2020): 28068-28079.

[15] S. AbuHammad, C. Cullinane, C. Martin, et al., “Regulation of PRMT5-MDM4 Axis Is Critical in the Response to CDK4/6 Inhibitors in Melanoma,” Proccedings of the National Academy of Sciences of the United States of America 116, no. 36 (2019): 17990-18000.

[16] Y. Qin, Q. Hu, J. Xu, et al., “PRMT5 enhances Tumorigenicity and Glycolysis in Pancreatic Cancer via the FBW7/cMyc Axis,” Cell Communication and Signaling 17, no. 1 (2019): 30.

[17] M. Liu, B. Yao, T. Gui, et al., “PRMT5-dependent Transcriptional Repression of c-Myc Target Genes Promotes Gastric Cancer Progression,” Theranostics 10, no. 10 (2020): 4437-4452.

[18] J. H. Liang, W. T. Wang, R. Wang, et al., “PRMT5 activates Lipid Metabolic Reprogramming via MYC Contributing to the Growth and Survival of Mantle Cell Lymphoma,” Cancer Letters 591 (2024): 216877.

[19] B. Ru, C. N. Wong, Y. Tong, et al., “TISIDB: An Integrated Repository Portal for Tumor-immune System Interactions,” Bioinformatics 35, no. 20 (2019): 4200-4202.

[20] K. Colwill and S. Gräslund, “A Roadmap to Generate Renewable Protein Binders to the human Proteome,” Nature Methods 8, no. 7 (2011): 551-558.

[21] B. Wienert, D. N. Nguyen, A. Guenther, et al., “Timed Inhibition of CDC7 Increases CRISPR-Cas9 Mediated Templated Repair,” Nature Communications 11, no. 1 (2020): 2109.

[22] S. F. Jin, H. L. Ma, Z. L. Liu, S. T. Fu, C. P. Zhang, and Y. He, “XL413, a Cell Division Cycle 7 Kinase Inhibitor Enhanced the Anti-fibrotic Effect of Pirfenidone on TGF-β1-stimulated C3H10T1/2 Cells via Smad2/4,” Experimental Cell Research 339, no. 2 (2015): 289-299.

[23] Q. Zhao, G. Rank, Y. T. Tan, et al., “PRMT5-mediated Methylation of Histone H4R3 Recruits DNMT3A, Coupling Histone and DNA Methylation in Gene Silencing,” Nature Structural & Molecular Biology 16, no. 3 (2009): 304-311.

[24] G. Egger, G. Liang, A. Aparicio, and P. A. Jones, “Epigenetics in human Disease and Prospects for Epigenetic Therapy,” Nature 429, no. 6990 (2004): 457-463.

[25] K. Chiang, A. E. Zielinska, A. M. Shaaban, et al., “PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression,” Cell Reports 21, no. 12 (2017): 3498-3513.

[26] H. S. Mueller, C. E. Fowler, S. Dalin, et al., “Acquired Resistance to PRMT5 Inhibition Induces Concomitant Collateral Sensitivity to paclitaxel,” Proccedings of the National Academy of Sciences of the United States of America 118, no. 34 (2021): e2024055118.

[27] Z. Wang, R. Li, N. Hou, et al., “PRMT5 reduces Immunotherapy Efficacy in Triple-negative Breast Cancer by Methylating KEAP1 and Inhibiting Ferroptosis,” Journal for ImmunoTherapy of Cancer 11, no. 6 (2023): e006890.

[28] E. C. Cho, S. Zheng, S. Munro, et al., “Arginine Methylation Controls Growth Regulation by E2F-1,” Embo Journal 31, no. 7 (2012): 1785-1797.

[29] S. Yin, L. Liu, C. Brobbey, et al., “PRMT5-mediated Arginine Methylation Activates AKT Kinase to Govern Tumorigenesis,” Nature Communications 12, no. 1 (2021): 3444.

[30] L. Wang, S. Pal, and S. Sif, “Protein Arginine Methyltransferase 5 Suppresses the Transcription of the RB family of Tumor Suppressors in Leukemia and Lymphoma Cells,” Molecular and Cellular Biology 28, no. 20 (2008): 6262-6277.

[31] P. Jing, N. Zhao, M. Ye, et al., “Protein Arginine Methyltransferase 5 Promotes Lung Cancer Metastasis via the Epigenetic Regulation of miR-99 family/FGFR3 Signaling,” Cancer Letters 427 (2018): 38-48.

[32] E. Hong, W. Barczak, S. Park, et al., “Combination Treatment of T1-44, a PRMT5 Inhibitor With Vactosertib, an Inhibitor of TGF-β Signaling, Inhibits Invasion and Prolongs Survival in a Mouse Model of Pancreatic Tumors,” Cell Death & Disease 14, no. 2 (2023): 93.

[33] L. Zhang, G. Shao, J. Shao, and J. Zhao, “PRMT5-activated c-Myc Promote Bladder Cancer Proliferation and Invasion Through Up-regulating NF-κB Pathway,” Tissue & Cell 76 (2022): 101788.

[34] X. Wen, S. Ling, W. Wu, et al., “Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma,” Digestive Diseases and Sciences 65, no. 4 (2020): 1064-1073.

[35] P. Song, L. Feng, J. Li, et al., “β-catenin Represses miR455-3p to Stimulate m6A Modification of HSF1 mRNA and Promote Its Translation in Colorectal Cancer,” Molecular Cancer 19, no. 1 (2020): 129.

[36] Z. Tang, B. Kang, C. Li, T. Chen, and Z. Zhang, “GEPIA2: An Enhanced Web Server for Large-scale Expression Profiling and Interactive Analysis,” Nucleic Acids Research. 47 (2019): W556-w560. W1.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.